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Summary N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymers containing doxorubicin (DOX) and
galactosamine can be targeted to the hepatocyte galactose receptor for organ-specific chemotherapy ofprimary
and metastatic liver cancer. Here we report the dose-dependent pharmacokinetics of this macromolecular
conjugate. Following intravenous administration to mice most efficient liver targeting was seen at low dose
(0.05 mg DOX kg-'), with receptor saturation observed using higher bolus doses. Repeated low dose bolus
injections did not cause down-regulation of the galactose receptor and targeted drug delivery rates of
> 2;g DOX g-I liver h-' were achieved. DOX is released from such conjugates intracellularly via action of
lysosomal proteinases. It was shown that isolated rat liver lysosomal enzymes (Tritosomes) can release
unmodified DOX from the peptidyl side chain Gly-Phe-Leu-Gly at a rate >3 fig DOX g- liver h-' i.e. the
hydrolytic capacity is greater than the observed rate of drug delivery to the liver lysosomes in vivo. Although
most conjugate would be captured by normal hepatocytes following intravenous administration, it was shown
that the human hepatoma cell line HepG2 retains the galactose receptor, accumulating and processing the
conjugate efficiently. Potential dose limiting toxicities of such drug conjugates could include cardio- or
hepatotoxicity. Administration of conjugate reduced the 15 min heart level of DOX approximately I00-fold
compared with that observed for an equivalent dose of free drug. Preliminary experiments showed that plasma
levels of alkaline phosphatase, alanine transaminase and asparate transaminase did not change following
administration of HPMA copolymer-daunorubicin (DNR) (10 mg DNR kg-') indicating no significant hepta-
toxicity.
On a worldwide basis, liver cancer is one of the major causes
of cancer mortalities. In Western Europe 20-25% of all
cancer deaths results from metastatic liver cancer, while in
parts of Africa and Asia primary hepatocellular carcinoma
alone accounts for nearly 40% (Cady, 1983; Nerenstone et
al., 1988). Surgical resection affords the possibility of cure for
localised tumours, but it is generally not suitable for patients
who present with diffuse disease. Similarly, chemotherapy is
effective in only a small percentage of cases, and the prog-
noses of patients with either primary or secondary liver
cancer are generally very poor (the 5-year survival rates for
primary hepatoma and liver-metastatic colorectal carcinoma
are only 3% and 2%, respectively).
Targeted drug delivery may permit improved chemo-
therapy of liver tumours at two different levels. At the first
level, a number of systems have been developed for liver-
specific therapy. The approach which has seen the most
clinical development to data involves infusion of drug-laden
microspheres into the hepatic artery, causing them to become
entrapped within the microvasculature with subsequent eleva-
tion of drug levels in the vicinity of tumour tissue (Kerr,
1989). However, the application of this technique is restricted
by its invasive nature, and intravenous delivery systems have
been sought. One such approach has used drug-laden nano-
particles that rapidly associate with Kupffer cells, from where
drug can diffuse into nearby tissues and produce high local
concentrations (Chiannilkulchai et al., 1989). Alternatively,
liver-specific targeting can be achieved intravenously using
vehicles designed to interact with liver-associated receptors,
such as the hepatocyte galactose receptor (Vera et al., 1985;
Ceulemans et al., 1987; Dragsten et al., 1987); the fenestrated
endothelial membrane of the liver allowing macromolecular
access to the hepatocyte surface, combined with the abun-
dant numbers of galactose receptors, makes them a suitable
target (Fallon & Schwartz, 1989).
At the second level therapy can be directed to the tumour,
for example by administration of antibodies interacting with
tumour-associated ligands, such as CEA and ferritin (Order
et al., 1980). Indeed, the hepatocyte galactose receptor itself
is retained by some human primary hepatomas (Schneider et
al., 1984) and may represent a useful target for the treatment
of this disease.
Following the observation that soluble N-(2-hydroxypro-
pyl)methacrylamide (HPMA) copolymers containing anthra-
cyclines display anti-tumour activity in vivo (Duncan et al.,
1989; Cassidy et al., 1989) we have explored the potential of
this polymer-based system for targeted delivery of doxo-
rubicin (DOX) to the hepatocyte galactose receptor. HPMA
Copolymers have previously been synthesised containing gal-
actose (Duncan et al., 1983a; Duncan et al., 1986; O'Hare et
al., 1989) and are known to associate with human hepatoma
cell lines in vitro (O'Hare et al., 1989) and also show liver-
targeting in vivo (Chytry et al., 1987). The galactose-targeted
polymer is associated with hepatocytes rather than non-
parenchymal cells, and it is transferred into lysosomes within
1 h of intravenous administration (Duncan et al., 1986).
Careful choice of the drug-polymer linkage can ensure that
the drug is released only following internalisation and subse-
quent cleavage by lysosomal enzymes; the conjugate is com-
pletely stable and inactive in the bloodstream (Duncan et al.,
1983b; Rejmanova et al., 1985).
To optimise drug targeting to the liver it is necessary to
understand the dose dependency of the galactose receptor,
and to identifiy the rate-limiting step in drug delivery. In
particular it is important to establish whether administration
of the targeted drug conjugate causes the receptor to become
down-regulated, and also to quantify the capacity of intracel-
lular lysosomal hydrolysis since this could limit the rate of
drug delivery. In addition the possibility of anthracycline
toxicity (particularly cardiotoxicity and hepatotoxicity)
should be assessed when the drug is presented in conjugate
form.
To address these questions HPMA copolymers were syn-
thesised containing DOX or daunorubicin (DNR) and galac-
tose. The kinetics of liver-targeting were assessed in vivo at
various doses using radioiodinated copolymers, and libera-
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tion of free drug from the conjugate was studied by HPLC in
vitro using isolated rat liver lysosomal enzymes, and also in
cultured human hepatoma cells (HepG2). The possibility of
cardiotoxicity was assessed by using HPLC techniques to
measure heart-levels of free drug, known to correlate with
anthracycline-induced cardiotoxicity; finally hepatotoxicity
was examined by monitoring the release into the plasma of a
number of hepatic enzymes conventionally used as markers
of liver damage.
Materials and methods
Materials
DOX was a kind gift of Farmitalia Carlo Erba (Milan,
Italy), and DNR was purchased from The Sigma Chemical
Co. (Poole, UK). All HPLC solvents were from Fisons plc
(Loughborough, UK), Hanks buffered salts solutions (HBSS)
and donor horse serum were purchased from Flow Labora-
tories (Rickmansworth, UK), and disposable Sephadex G-25
chromatography columns (PDI0) were from Pharmacia Ltd
(Milton Keynes, UK). DBA2 mice (male, approximately 10
weeks old) were purchased from Bantin and Kingman Ltd
(Hull, UK).
Synthesis ofdoxorubicin-copolymer conjugates
HPMA copolymer conjugates containing DOX and, in some
cases additionally galactosamine were synthesised as de-
scribed previously (Rihova et al., 1989). The weight average
molecular weight and polydispersity of the polymeric precur-
sors (before conjugation to DOX or sugar) were determined
using Sepharose 4B/6B gel permeation chromatography
(Strohalm & Kopecek, 1978). To facilitate radioiodination,
certain copolymers were prepared which contained methacry-
loyltyrosinamide as comonomer (1.0 mol%) units (Duncan et
al., 1981). Chemical characteristics of the polymer conjugates
are shown in Table I and the structure of Conjugate 3 is
represented in Figure 1.
Measurement ofpharmacokinetics in DBA2 mice using
radioactivity
Tyrosinamide-containing copolymers were radiolabelled with
1251I iodide using an iodogen technique (Seymour et al., 1990),
to give a specific activity of approximately 50 giCi mg l con-
jugate. Materials were always purified by Sephadex G-25
column chromatography immediately prior to use in order to
remove all free 1251 iodide.
To quantitate blood clearance and liver accumulation it
was important first to estimate precisely the DBA2 mouse
circulation volume available to DOX-HPMA copolymer con-
jugates. 251I-Labelled Conjugate 1 (not containing galactos-
amine) was considered the most appropriate probe for this
purpose due to its relatively slow blood clearance (Seymour
et al., 1990). It was administered intravenously (via the tail
vein, at a dose of 0.05 mg DOX kg-') and a blood sample
(20ptl) taken 1 min later. Assay of the radioactivity content
of the sample, together with knowledge of the amount of
radioactivity administered, permitted the dispersion volume
to be calculated. Using this technique the blood volume (for
HPMA-DOX) was found to be 8.64 ± 0.25 ml blood 100 g-'
body weight. In the same experiment the liver was isolated,
rinsed in cold phosphate buffered saline, weighed, homo-
genised in water to a known volume and assayed for contain-
ed radioactivity. Assuming that the radioactivity associated
with liver at 1 min was due entirely to polymer-conjugate
present in ocluded blood, it is possible (using the amount of
radioactivity detected in the blood sample) to calculate the
volume of blood occluded in the liver and this was found to
be 0.14 ± 0.01 ml g-' liver. The above values were used
throughout to calculate the blood volume and blood occlud-
ed in the liver.
For subsequent studies substrates were injected via the tail
vein into lightly-anaesthetised DBA2 mice at known total
doses of DOX, and the 251I-labelled conjugates (1 and 3) were
always administered at a dose of DOX equal to 0.05 mg
kg-'. To study the dose dependancy of clearance and liver
accumulation of galactosamine-containing polymers the non-
radiolabelled Conjugate 2 was coadministered with the radio-
labelled Conjugate 3 to give a total DOX dose of 0.05-15.0
mg kg-'. Mice were maintained under anaesthetic through-
out, and blood samples (20 slI) were taken from the tail over
a 60min period and assayed for radioactivity. The initial
blood level was calculated from knowledge of the total radio-
active dose administered and the volume of dispersion calcul-
ated above. After 60 min animals were killed by cervical
dislocation and the liver removed, rinsed in phosphate-buffer-
ed saline, and homogenised in a known total volume of water
prior to radioactivity assay. The radioactivity present in the
carcass and excreta were measured following its dissolution
in sodium hydroxide (10.0 M, 850C, 60min).
In certain experiments multiple doses of polymer-DOX
were administered. The first series of experiments involved
intravenous injection of Conjugate 2 (5.0 mg DOX g-'),
followed (24 h later) by administration of radiolabelled Con-
jugate 3 (0.05 mg DOX kg-'). Blood samples were taken
over a 60 min period following the latter injection. A second
series of experiments was carried out in which hourly doses
of polymer-DOX (0.5 mg DOX kg-') were given for periods
Table I Chemical characterisation of HPMA copolymers
Polymer Substitution
Code No. Structure (mol%) (wt%drug) Mwa M./Mna
I TyrNH2 230 87 22 000 1.4
2 p Gly-Phe-Leu-Gly-DOX 2.4 7.3 19 000 1.4 Gly-Phe-Leu-Gly-Gal 4.0 190 .
TyrNH2 1.0
3 P- Gly-Phe-Leu-Gly-DOX 1.8 6.2 25 000 1.4
Gly-Phe-Leu-Gly-Gal 2.0 -
4 P- Gly-Phe-Leu-Gly-DOX 2.5 8.5 24 000 1.4
5 P- Gly-Gly-DOX 1.2 4.3 23 000 1.4
TyrNH2 1.0 -
6 P- Gly-Phe-Leu-Gly-DNR 2.7 7.3 17 000 1.3
Gly-Phe-Leu-Gly-Gal 4.0 -
aValues of M. and MW/Mn (polydispersity) were calculated from gel permeation
chromatography data (Strohalm & Kopecek, 1978). The chromatography column
(1.6 x 90 cm)waspackedwith Sepharose4B and 6B(1:1)andelutionwasataflowrateof
11 ml h-' in TRIS buffer (0.05 M, pH 8.0) containing NaCI (0.5 M). The column was
calibratedusingstandards ofpolyHPMA. Abbreviations: P -polymerbackbone; DOX -
doxorubicin; Gal - galactosamine; DNR - daunorubicin.TARGETING DRUGS TO HEPATIC GALACTOSE RECEPTORS 861
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Figure 1 Structure of HPMA copolymer containing doxorubicin. The chemical composition of Conjugate 3, containing tyrosin-
amide and galactosamine is shown.
up to 4 h. In every case only the last injection contained
'25I-labelled Conjugate 3, earlier injections being non
radiolabelled Conjugate 2.
Quantitation ofDOX in heart tissue using HPLC
Conjugate 2 was administered caudally to lightly-anaes-
thetised mice at a dose of 5 mg DOX kg-'; animals were
allowed to recover consciousness and at intervals they were
killed by cervical dislocation. Hearts were removed, washed
in cold saline and immediately frozen. Free and polymer-
bound DOX was assayed using HPLC methods previously
described. Free DOX was determined in samples of organ-
homogenates by a modification of the method of Cummings
et al. (1984) and quantitation of polymer-bound DOX was
achieved by releasing the DOX from the conjugate using
acid-hydrolysis (Seymour et al., 1990).
Degraduation ofHPMA copolymer-DOXby lysosomal
enzymes in vitro
Male Wistar rats were injected intraperitoneally with the
detergent Triton WR1339 and 4 days later their liver lyso-
somes (Tritosomes) were purified using methods previously
described (Trouet, 1974). To examine the effect of substrate
concentration on degradation, Tritosomes (40%, v/v) were
incubated with Conjugate 4 at a range of concentrations
(2.5-20.0 g DOXml-'), in the presence of reduced gluta-
thione (5 mM) and EDTA (1 mM) in citrate phosphate buffer
(0.2 M, pH 5.5 containing Triton X-100 (0.2%)) at 37°C.
Samples (0.1 ml) were removed hourly up to 5 h and immedi-
ately frozen in liquid nitrogen pending HPLC-analysis.
Alternatively, to examine the effect of enzyme concentration
on degraduation, Tritosomes were incubated at a range of
concentrations (5-40%, v/v) with Conjugate 4 (5gg DOX
ml-') and processed as described above. The presence or
absence ofgalactose in the conjugates is known to be without
effect on their rate of degradation by Tritosomes (Ulbrich,
unpublished observations). To study the release of DOX
from a tetrapeptide (Gly-Phe-Leu-Gly) side chain compared
with a dipeptide (Gly-Gly) side chain, Tritosomes (40%, v/v)
were also incubated (up to 24h) as described above with
either Conjugate 4 or Conjugate 5 at a final concentration of
60jg DOXml-'.862 L.W. SEYMOUR et al.
Uptake ofHPMA copolymer-DOX by HepG2 in vitro
HepG2 cells were incubated with Conjugates 2 and 4 (1Ofig
DOX ml') and the rate of cell-accumulation of DOX was
assessed. Cell-associated drug was distinguished into poly-
mer-bound DOX and free DOX which had been cleaved
from the polymer conjugate. After 0-72 h cells were washed
in PBS (5.0 ml), harvested using trypsin (5.0 ml), isolated by
centrifugation (1000g, 4°C, Omin) and resuspended in PBS
(1.4ml/sample) before disruption by rapid freezing in liquid
nitrogen and thawing. They were then passed through a
narrow gauge syringe needle, and an internal standard of
DNM (600 ng 0.1 ml-' in water) added to each. Aliquot
samples (3 x 50 sl) were assayed for protein using the
method of Peterson (1983). DOX content was measured
using HPLC; each sample was divided into volumes of 0.3
and 1.0 ml for determination of free and polymer-bound
DOX, respectively. For analysis of free DOX, 0.1 ml of
ammonium formate buffer (pH 8.5, 1.0 M) and 5.0ml chloro-
form:propan-2-ol (4:1, v:v) was added to each sample
(0.3 ml). Samples were then mixed thoroughly by vortexing,
and centrifuged (1000 g, 60 min, 4°C) to promote phase-
separation. The aqueous phase and precipitated protein com-
ponent was removed using a vacuum line, and the organic
phase evaporated to dryness under a nitrogen stream using a
Techne sample concentrator. Samples were dissolved in Ana-
lar grade methanol (50fil) prior to HPLC analysis (injection
volume 20 gl) using a g-Bondapak C18 column (Millipore-
Waters), and eluted (1.0 ml min-) using a mobile phase of
aqueous propan-2-ol (29%) adjusted to pH 3.2 with ortho-
phosphoric acid. To permit quantitation of polymer-bound
DOX, an acid-hydrolysis stage was incorporated into this
protocol (Seymour et al., 1990).
Assessment ofhepatotoxicity ofgalactose-targeted
anthracyclines
To assess possible hepatotoxicity of liver targeted anthra-
cyclines, Conjugate 6 (Table I) was administered i.v. (tail
vein) to male To mice (12 weeks old, approximately 40 g) at
a dose of 10mg DNRkg-' body weight. Mice, including
saline-treated controls, were weighed at intervals up to 28
days and blood samples were taken from the orbital sinus
into heparinised tubes for enzyme assay. Levels of alanine
transaminase (a cytoplasmic liver enzyme released when
hepatocellular damage occurs, Zilva & Pannall, 1981), aspar-
tate transaminase (present in the cytoplasm and mitochon-
dria of liver cells, and also released following hepatic
damage) and alkaline phosphatases (largely associated with
cells ofthe bile cannaliculi) were measured. All three enzymes
were assayed using the standard kits purchased from Boeh-
ringer Mannheim (UK) Ltd (Lewes, East Sussex).
Results
Pharmacokinetic studies using radio-iodinatedpolymer
conjugates
Following a single bolus injection, the rate of bloodclearance
of '25I-labelled Conjugate 2 was markedly influenced by dose
(Figure 2). At very low doses (0.05 mg DOXkg-') blood-
clearance was fast, most of the radioactivity having disap-
peared from the bloodstream within the first 20min. Elevating
the dose caused a slowing ofthe rate ofbloodclearance, and at
15 mg DOX kg-1, the profile ofbloodclearance was essentially
identical to that of the non galactose-containing Conjugate 1.
The effect of multiple bolus injections was examined using
two schedules. In the first series of experiments it was shown
(Figure 3a) that the bloodclearance profile of a small dose
(0.05 mg DOXkg-') of radiolabelled Conjugate 3 given 24 h
following a large dose (5.0 mg DOX kg-') of Conjugate 2
was indistinguishable from the clearance observed in pre-
viously untreated animals, indicating that the receptor is not
permanently saturated or down regulated by the higher dose.
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Figure 2 Effect of administered dose on the bloodclearance
of HPMA copolymer-DOX containing galactosamine. Blood-
clearance of Conjugate 3 was measured following intravenous
bolus administration of 0.05 mg kg-' (0 0), 0.5 mg kg-'
(A A), Smgkg-} (O *) or 15.Omgkg-' (A A)
related to the DOX content of the conjugate. Bloodclearance of
Conjugate 1 (O 0) administered at a dose of 0.05 mg
DOX kg-' is shown for comparison. Each point represents the
mean of at least three determinations±standard error.
In subsequent experiments bloodclearance of repeated doses
(administered hourly) of conjugate (0.5 mg DOXkg-') was
followed. Up to four consecutive hourly doses were given
and Conjugate 3 was cleared from the bloodstream at the
same rate throughout (Figure 3b).
The liver accumulation of radiolabelled Conjugate 2 after
1 h was greatest (up to 45% of the dose administered) at the
lowest doses examined (0.5 mg DOXkg-'). Because a large
proportion (over 25%) of the administered conjugate is lost
via urinary excretion during the 60 min experiment, this
amount accounts for over 70% of the radioactivity remaining
in the body at the time of sampling. Increasing the dose of
conjugate resulted in decreased efficiency of liver-targeting; at
doses of Conjugate 2 containing 5 mg DOX kg-' and above
the radioactivity recovery in the liver was only 2-4% of that
administered (Figure 4a). Expression of DOX accumulation
by the liver in absolute amounts (ng DOX g- liver) as a
function of dose shows a biphasic profile with an initial steep
rise (up to 0.5 mg DOX kg-'), and then a slower increase
directly proportional to the dose administered (Figure 4b).
Lysosomal degradation ofconjugates in vitro
When Conjugate 4 (at various concentrations) was incubated
with Tritosomes in vitro, there was progressive release (linear
with time up to 5 h) of anthracycline, appearing as a single
peak on HPLC analysis (co-eluting with free DOX). Increas-
ing substrate concentration caused a fall in the percentage of
polymer-bound DOX released over the 5 h (again linear with
time over this period), although the absolute amount liber-
ated was independent of concentration (Table II). Clearly
under these conditions the concentration ofenzymes, and not
substrate, was rate-limiting; the amount of DOX released
over 5 h increased approximately linearly with the concentra-
tion of added enzyme.TARGETING DRUGS TO HEPATIC GALACTOSE RECEPTORS
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Figure 3 Effect of repeat intravenous dosing on the clearance of
HPMA copolymer-DOX containing galactosamine. a, shows the
bloodclearance of Conjugate 3 (0.05 mg DOX kg-') measured
24 h after administration of Conjugate 2 (5.0 mg DOX kg- ',
0 0), and also the clearance of Conjugate 3 (0.05 mg
DOX kg-') administered to unpretreated mice (0 *). Each
point represents the mean of at least three determinations ± stan-
dard error. In b, Conjugate 2 (at a dose of 0.5 mg DOX kg-')
was administered hourly, up to four times, and bloodclearance of
the last dose given was monitored using an intravenous bolus (see
arrow) of '25l-labelled Conjugate 3. Each point represents a single
blood sample.
Tritosomes achieved rapid cleavage of DOX from Conju-
gate 4, which contains the tetrapeptide Gly-Phe-Leu-Gly as
drug-polymer linkage; however there was no significant Tri-
tosome release of DOX from Conjugate 5, which contains
the dipeptide spacer Gly-Gly (Figure 5).
Uptake and degradation ofconjugates in vitro by HepG2 cells
Conjugate 2 showed accumulation by HepG2 cells at a rate
greater than 15 ng DOX mg-' cell protein h-' (Figure 6),
reaching a steady-state of about 400 ng mg-' cell protein.
This accumulation is predominantly galactose-mediated, since
galactose free control (Conjugate 4) was only taken up slow-
ly, at about 2 ng mg- i cell protein h-1. Rates of uptake may
be slight underestimates since they take no account of DOX-
metabolism, or of free DOX released back into the medium.
Both conjugates underwent intracellular hydrolysis to release
free DOX, demonstrating the ability of human lysosomal
enzymes to hydrolyse this tetrapeptide drug-polymer linkage.
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Figure 4 Effect of administered dose on the liver deposition of
'25I-labelled HPMA copolymer-DOX containing galactosamine.
Following measurement of bloodclearance (shown in Figure 2)
the DOX content of the liver after 1 h was measured as described
in the Methods section. Liver accumulation is expressed a as %
total DOX administered per g of liver tissue, or b, as the absolute
amount of DOX recovered (jugg-I of liver). Each point repre-
sents the mean of at least three determinations ±standard error.
Table II Degradation of Conjugate 4 in vitro by rat liver lysosomal
enzymes
(a) The effect of substrate concentration on DOX releasea
Concentration ofsubstrate DOX released
g DOXml-) (% totalS h'-) (igml-'5 h)
17 52.9 9.00
35 21.8 7.62
69 14.0 9.68
104 8.9 9.30
138 6.7 9.18
(b) The effect of enzyme concentration on DOX releaseb
Concentration oftritosomes DOX released
% (v/v)) (% total5h-') (pgml-'Sh-')
5 2.08 1.04
10 4.2 2.11
20 5.2 2.58
30 10.5 5.25
40 12.6 6.29
allIassayswereperformed atatritosomeconcentrationof40% (v/v).
bAll assays were performed using a concentration ofsubstrate of501tg
DOX mlh'.
Measurement ofheart levels ofDOX
A peak heart level for free DOX of about 12ytg DOX g-'
tissue was detected 15 min following administration of free
DOX (5 mgkg-'); this was decreased 100-fold when the drug
was given at equal dose in conjugate form (Figure 7). The
amount of free DOX detected in the heart following adminis-
tration of galactose-targeted conjugate was the same as
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Figure 5 Degraduation of HPMA copolymer-DOX by lyso-
somal enzymes in vitro. Release of DOX from P-Gly-Phe-Gly-
DOX (0, Conjugate 4) and P-Gly-Gly-DOX (0, Conjugate 5) is
shown.
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Figure 6 Accumulation of Conjugate 2 by human hepatoma cell
line (HepG2) in vitro. Uptake was monitored over 72h using
HPLC, as described in the text. Levels both of total (including
polymer-bound) DOX ( ) and free DOX (--) detected in
the cells were determined following incubation in the presence of
Conjugates 2 (O) and 4 (0). Each point represents the mean of
at least three different determinations±standard error.
reported previously (Seymour et al., 1990) for non-targeted
formulations; the presence ofgalactose has no apparent effect
on free drug levels in the heart.
Assessment ofrelease ofliver enzymes
Mice administered Conjugate 6 (10mg DNRkg-') showed
no differences from controls in either body weight or in the
plasma levels of alanine transaminase, aspartate transaminase
or alkaline phosphatase over the duration of the experiment.
On autopsy their livers appeared to be normal (results not
shown).
Discussion
HPMA copolymers without targeting residues (such as
Conjugate 1) show kinetics of bloodclearance and body
60 min
Time
24 h 7 days
Figure 7 DOX concentration in the heart following intravenous
administration of free and polymer-bound DOX. Conjugate 2
(5 mg DOX kg-') was administered intravenously and the free
DOX (0) measured using HPLC. Results obtained were com-
pared to those detected following administration of free DOX
(5 mgkg-') (0).
distribution governed mainly by molecular weight-dependent
extravasation and glomerular filtration (Seymour et al.,
1987). Their slow accumulation by cells is via fluid-phase
pinocytosis (Duncan et al., 1981), an uptake mechanism
which is not saturable and where the amount of material
captured is directly proportional to its concentration in the
extracellular fluid (Williams et al., 1975a). In contrast,
copolymers containing targeting residues (e.g. Conjugate 2)
can also enter target cells by receptor-mediated pinocytosis.
This process involves the substrate binding to specific recep-
tors on the plasma membrane and constitutes an efficient
method of uptake at low substrate concentrations, although
it typically shows receptor-saturation at high concentrations
(Williams et al., 1975b).
In this study we have examined the kinetics of galactose-
targeted polymer-doxorubicin conjugates which are princi-
pally suitable for organ-specific therapy of primary and
secondary liver cancer. We found that bloodclearance of
intravenously injected galactose-targeted conjugates was very
rapid at low doses (Figure 2), and the material was captured
efficiently by the liver (Figure 4a). With increasing dose, the
rate of bloodclearance and liver accumulation gradually fell
(in percentage terms) until, at a dose of 15 mgkg', behav-
iour was indistinguishable from that of a galactose-free con-
trol polymer.
When liver-deposition is expressed in absolute quantities of
DOX it is clear that at low doses there was enhanced accu-
mulation due to galactose-mediated pinocytosis, while at
higher doses the amount of material accumulated was pro-
portional to the dose, suggesting uptake by a non-specific
process such as fluid-phase pinocytosis. Kooistra et al. (1979)
showed the hepatic rate of fluid-phase accumulation of 1251_
labelled poly(vinylpyrrolidone) to be approximately 1.6 ml
plasma/day in the rat. Simple conversion on a weight basis
suggests the corresponding figure for mouse liver would
be approximately 0.01 ml plasma/mouse/h (or 1% plasma
volume/h-'). Data shown in Figure 4b indicate a rate of
non-specific clearance of Conjugate 2 to be equivalent to
3-4% plasma volume/h-'; therefore other factors (such as
non-specific adsorptive pinocytosis) may also contribute to
the liver capture of galactose-targeted HPMA copolymer-
DOX conjugates. This would not be surprising in view of the
affinity of DOX for interaction with membranes (Brown &
Imam, 1984).
The efficiency of liver-targeting of Conjugate 2 observed
here can be compared with extensive literature describing the
physiological functioning of the galactose receptor. EstimatesTARGETING DRUGS TO HEPATIC GALACTOSE RECEPTORS 865
of average rate of uptake of galactose-bearing macromole-
cules by isolated rat hepatocytes are about 4 x 106 molecules
internalised/cell/h (Warren & Doyle, 1981; Schwartz et al.,
1982). Given that there are about 1.6 x 108 cellsg-' moist
liver (Pardridge et al., 1983) this would correspond to a total
uptake rate of 6.4 x 10'4 moleculesg-' liver-' h-'. Since
molecules of Conjugate 2 contain, on average, three drug
units, a rate of accumulation of about 2 x 10'5 molecules of
DOXg-' liver-lh-' (equivalent to approximately 2pg
DOX g liver-' h-') would be expected. This theoretical value
is in good agreement with the observed quantity of DOX
selectively targeted to the liver in vivo after administration of
Conjugate 2. In terms of clinical relevance, it should be
stressed, however, that although the galactose receptor has
been shown to exist in human livers (Baenziger & Maynard,
1980), levels are known to show considerable variation
between mammals (including mice, guinea pigs, rats and
rabbits (Chang & Chang, 1988)); there is, as yet, no definitive
study of the saturability of the receptor in man.
In addition to organ-specific drug delivery, targeting to the
galactose receptor may also permit tumour-selective therapy
since some human primary hepatomas are known to retain
the galactose receptor (Schneider et al., 1984). The frequency
of receptor retention is still a matter for debate, however; for
example Virgolini et al. (1990) using 9'Tc-galactosylated
neoglycoalbumin, showed localisation of the radioligand in
normal liver tissue of patients with hepatoma or liver metas-
tases, but SPECT imaging suggested no uptake by malignant
tissue. A number of human hepatoma cell lines (including
HepG2 and Alexander) are known to express the galactose
receptor however (O'Hare et al., 1989), and here we have
used the cell line HepG2 to study cellular processing of
galactose-targeting doxorubicin (Conjugate 2). Under in vitro
conditions thought to be near-saturating, we found an up-
take rate in excess of 15 ng DOXmg-1 cell proteinh-', a
7-fold increase over the rate of accumulation of galactose-
free conjugates. The rapid appearance of free intracellular
DOX shows clearly that lysosomal enzymes of human origin
degrade the tetrapeptide drug-polymer linkage, liberating free
drug after cellular internalisation (Figure 6).
The polymer conjugates described here can be thought of
as macromolecular prodrugs as they require activation by
lysosomal enzymes in vivo to release free DOX. It is therefore
important to establish whether the liver lysosomal enymes
have adequate proteolytic capacity to hydrolyse the quanti-
ties of drug conjugate that will be presented to them during
therapy. Otherwise lysosomal enzyme activity rather than
galactose-mediated targeting would constitute the rate limit-
ing step for drug delivery. Use of isolated Tritosomes permits
direct study of kinetic parameters relating to lysosomal
degradation (Duncan et al., 1983c). It should be noted, how-
ever, that the enzymes probably function less efficiently in
vitro, not least because of their significantly decreased con-
centration; nevertheless, careful interpretation of the data can
yield valuable insights into lysosomal processing. It was
shown in vitro that lysosomal enzymes cleave DOX efficiently
from conjugates containing a tetrapeptide (Gly-Phe-Leu-Gly)
linkage, but not from conjugates with a dipeptide (Gly-Gly)
linkage (Figure 5). These observations correlate well with the
known antitumour activity of the form type of conjugates
and the lack of activity of the latter (Duncan et al., 1989).
In addition, the rate of cleavage of DOX from the tetra-
peptide-based conjugate was assessed at a range of enzyme
concentrations, under saturating conditions. After making
corrections for efficiencies of enzyme extraction, the rate of
release of DOX in vitro was found to correspond to an in
vivo rate of 3.14 ± 0.36gg DOX g liver-' h-'. This is cer-
tainly not an overestimate of the in vivo processing ability of
the lysosomes and, for reasons mentioned above, it is prob- ably an underestimate. Nonetheless it serves to demonstrate
that the lysosomal enzymes should be capable ofcleaving the
quantity of conjugate that can be targeted to the galactose
receptor of the liver using this system (2-3 1ig g liver' h-')
and will not themselves constitute the rate-limiting step.
Cumulative cardiotoxicity is a major factor limiting the
clinical application of free DOX. Patients receiving a total
dose in excess of 500-600 mgkg' often develop a degener-
ative cardiomyopathy that can be life-threatening. Previously
we have seen (Seymour et al., 1990) that conjugation of
DOX to HPMA copolymers can decrease the 15 min heart
level of free drug by about 100-fold, and here we have shown
that the same is true for HPMA-DOX conjugates containing
galactose (Figure 7). In a sensitive test for anthracycline-
mediated cardiotoxicity in rats, measuring cardiac output, the
toxicity of the polymer conjugate has been shown to be
substantially decreased compared with equivalent doses of
the free drug (Yeung et al., 1989).
Ability to treat liver cancer with organ-specific delivery of
DOX is crucially dependent on the ability of the drug to act
selectively against tumour cells, without causing excessive
damage to normal hepatocytes. Since hepatocytes are the
main site of DOX metabolism, with a slow rate of cell
division, they may be relatively resistant to DOX toxicity. In
tests ofhepatotoxicity, plasma levels of alanine transaminase,
aspartate transaminase and alkaline phosphatase (conven-
tional markers of liver damage) were measured following
administration of a single dose (10mg DNRkg-') of gal-
HPMA-DNR (Conjugate 6). There was no change, relative
to controls, in the plasma levels of any of the enzymes tested
over the following 28 days. Although the kinetics of adminis-
tration of this conjugate were not optimised for targeting, it
is encouraging to note that even at this high dose there were
no indications of liver damage.
Observations reported here have important implications
for the clinical use of galactose-targeted formulations of
DOX. It is clear that bolus administration of high doses of
Conjugate 2 does not produce the most efficient liver-target-
ing; instead a large percentage of the dose administered
remains in the circulation, subsequently being lost mainly in
the urine. To achieve optimal liver-targeting using conjugates
of molecular weight 20 kD it would be necessary to use either
continuous low dose infusion (this has been used clinically to
deliver DOX (Shapira et al., 1990)), or repeat bolus injections
at doses achieving efficient targeting. Hourly repeated bolus
injections of 0.5 mg DOX kg-' (as Conjugate 2) produced
selective liver deposition in mice equivalent to 25% of the
dose at each administration. Neither this regime nor a single
high-dose bolus (followed after 24 h by low dose injection)
seemed to impair the galactose recognition system irrever-
sibly.
The efficiency of galactose-targeting of drug conjugates
may be improved by manipulation of their molecular weight.
It is known that the weight average molecular weight thres-
hold limiting glomerular passage of HPMA copolymers is
about 45 kD (Seymour et al., 1987), and the use of con-
jugates of molecular weight higher than this would prevent
rapid renal elimination. The galactose receptors of the liver
are the only quantitatively-significant galactose recognition
systems in the body (Schlesinger et al., 1980); hence administ-
ration of large doses of a high molecular weight drug con-
jugate, although initially saturating the liver receptors, should
allow the excess to remain in the circulation thus being
available for capture by the recycling hepatic galactose recep-
tors. Such conjugates would permit single high dose bolus
injections leading to selective liver-deposition of therapeu-
tically useful quantities of drug, and they are currently
undergoing extensive pharmacokinetic evaluation and testing
against animal models of hepatic malignancies.
We would like to thank the Cancer Research Campaign for support-
ing this research and the Royal Society for sponsoring the Interna-
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